A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association o

[1]  S. Treon,et al.  CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib , 2019, British journal of haematology.

[2]  N. Munshi,et al.  Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. , 2018, Blood advances.

[3]  J. Lim,et al.  Genetic analysis of Diffuse Large B‐cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinaemia reveals different patterns of clonal evolution , 2018, British journal of haematology.

[4]  M. Dimopoulos,et al.  Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies , 2018, Leukemia.

[5]  M. Huibers,et al.  The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid , 2018, Hematological oncology.

[6]  S. Treon,et al.  Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound , 2018, American journal of hematology.

[7]  Alese E. Halvorson,et al.  MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia , 2018, American journal of hematology.

[8]  S. Treon,et al.  MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival , 2018, British journal of haematology.

[9]  S. Leprêtre,et al.  Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO) , 2017, British journal of haematology.

[10]  M. Cazzola,et al.  Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance , 2017, Haematologica.

[11]  T. Habermann,et al.  Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 , 2017, JAMA oncology.

[12]  G. R. Ordóñez,et al.  From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation , 2017, Blood Cancer Journal.

[13]  S. Treon,et al.  Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia , 2017, British journal of haematology.

[14]  Anthony T Papenfuss,et al.  Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia , 2017, Nature Communications.

[15]  M. Kersten,et al.  Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM‐8 consensus panel , 2017, British journal of haematology.

[16]  M. Kersten,et al.  Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome , 2017, Haematologica.

[17]  A. Zannettino,et al.  Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group , 2017, Internal medicine journal.

[18]  R. Advani,et al.  Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia , 2016 .

[19]  S. Leprêtre,et al.  Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO) , 2016 .

[20]  P. Hawkins,et al.  European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Marcos González,et al.  Origin of Waldenstrom's macroglobulinaemia. , 2016, Best practice & research. Clinical haematology.

[22]  S. Chevret,et al.  IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia , 2016, Clinical Cancer Research.

[23]  B. Quesnel,et al.  Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia , 2015, Clinical Cancer Research.

[24]  S. Treon,et al.  MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. , 2015, The New England journal of medicine.

[25]  A. Órfão,et al.  The cellular origin and malignant transformation of Waldenström macroglobulinemia. , 2015, Blood.

[26]  A. Foli,et al.  A practical approach to the diagnosis of systemic amyloidoses. , 2015, Blood.

[27]  B. Quesnel,et al.  MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome , 2014, British journal of haematology.

[28]  C. Kyriakou,et al.  Guidelines on the diagnosis and management of Waldenström macroglobulinaemia , 2014, British journal of haematology.

[29]  S. Treon,et al.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.

[30]  B. Quesnel,et al.  Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia , 2013, American journal of hematology.

[31]  S. Chevret,et al.  Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia , 2013, Haematologica.

[32]  David T Yang,et al.  Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. , 2013, Archives of pathology & laboratory medicine.

[33]  S. Treon,et al.  Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. , 2013, Clinical lymphoma, myeloma & leukemia.

[34]  R. de Tute,et al.  Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells. , 2013, Clinical lymphoma, myeloma & leukemia.

[35]  M. Cazzola,et al.  Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. , 2013, Blood.

[36]  N. Munshi,et al.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. , 2013, Blood.

[37]  E. Kimby,et al.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop , 2013, British journal of haematology.

[38]  I. Ghobrial.  Are you sure this is Waldenstrom macroglobulinemia? , 2012, Hematology. American Society of Hematology. Education Program.

[39]  S. Susen,et al.  Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. , 2012, Blood.

[40]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[41]  R. Vij,et al.  Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005 , 2012, Leukemia & lymphoma.

[42]  T. Sun.  Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms , 2011 .

[43]  S. Pasricha,et al.  Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenström macroglobulinaemia , 2011, Journal of Clinical Pathology.

[44]  A. Dispenzieri,et al.  Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. , 2009, Blood.

[45]  E. Ryu,et al.  Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. , 2009, Clinical chemistry.

[46]  J. Crowley,et al.  International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.

[47]  U. Surti,et al.  Fluorescence Immunophenotypic and Interphase Cytogenetic Characterization of Nodal Lymphoplasmacytic Lymphoma , 2008, The American journal of surgical pathology.

[48]  A. Porwit,et al.  ICSH guidelines for the standardization of bone marrow specimens and reports , 2008, International journal of laboratory hematology.

[49]  N. Raje,et al.  Neurological manifestations of Waldenström macroglobulinemia , 2008, Nature Clinical Practice Neurology.

[50]  R. Kyle,et al.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. , 2007, Hematology/oncology clinics of North America.

[51]  J. Hernández-Rivas,et al.  6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis , 2007, British journal of haematology.

[52]  J. Kutok,et al.  Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  M. Rue,et al.  Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia , 2004, Cancer.

[54]  S. Treon,et al.  Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  T. Therneau,et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.

[56]  M. Nordberg,et al.  Fluorescence in situ hybridization: Method of choice for a definitive diagnosis of mantle cell lymphoma † , 2003, American journal of hematology.

[57]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[58]  T. Lister,et al.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[59]  S. Montoto,et al.  Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.

[60]  S. Barbieri,et al.  Frequency and clinical correlates of anti–neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy , 1994, Annals of neurology.

[61]  M. Dimopoulos,et al.  Waldenström's macroglobulinemia: clinical features, complications, and management. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.